MetaVia (MTVA) to Release Quarterly Earnings on Thursday

Posted by Patrick Bannon on Mar 17th, 2026

MetaVia (NASDAQ:MTVA – Get Free Report) is projected to post its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect MetaVia to post earnings of ($2.06) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 26, 2026 at 12:30 PM ET.

MetaVia Price Performance

Shares of MTVA opened at $1.52 on Wednesday. The company has a market capitalization of $3.34 million, a P/E ratio of -0.18 and a beta of 0.33. MetaVia has a one year low of $1.34 and a one year high of $23.10. The business’s 50 day simple moving average is $2.65 and its 200-day simple moving average is $7.13.

Analysts Set New Price Targets

MTVA has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a report on Monday, December 22nd. Wall Street Zen cut MetaVia from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, HC Wainwright raised their target price on MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, MetaVia has a consensus rating of “Hold” and a consensus target price of $36.50.

View Our Latest Report on MetaVia

Hedge Funds Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new stake in shares of MetaVia Inc. (NASDAQ:MTVA – Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent quarter. Institutional investors own 1.37% of the company’s stock.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.